iBio reports Q2 EPS (9c), consensus (6c)

iBio (IBIO) held cash, cash equivalents and investments in debt securities of $52.7M as of December 31, 2025. “We have significantly advanced our preclinical pipeline programs – IBIO-610, our activin E antibody, and IBIO-600, our myostatin antibody – towards the start of human clinical trials by initiating CMC development and toxicology studies,” said Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio. “Additionally, we recently completed a $26 million private placement financing with a highly respected biotech investor, strengthening our resources for pipeline progress and taking us one step closer to fulfilling our mission of reaching patients in need of an accessible, transformative therapy for obesity. The positive news positions us well to execute on our planned milestones and corporate priorities throughout 2026 and 2027.”